Early Diagnosis Saves Lives: Meril and Madiha’s Fight Against Pompe Disease
In this video, Madiha and Meril's journey with rare metabolic disorders is shared. Madiha, initially a healthy child, started experiencing severe muscle weakness and developmental delays by 6 months of age. After extensive tests, she was diagnosed with Alpha-Glucosidase Deficiency, also known as GSD Type II. With no improvement from initial treatments, her mother had to feed her through a tube for 8 months. Thanks to the free access to medicines through the Indian Charitable Access Program, Madiha’s health has improved significantly, and she is now thriving, defying early expectations.
Meril's health challenges began in 7th grade, when she experienced muscle weakness, which led doctors to initially suspect muscular dystrophy. However, after further testing in 2010, Meril was diagnosed with Pompe disease. After starting enzyme replacement therapy (ERT), her health showed significant improvement. Today, Meril is living a normal life, thanks to early diagnosis and timely treatment.
MAT-IN-2301070
leave-site-modal-text
You are now being redirected to a third-party website.
Sanofi does not endorse or approve the content, products, services or opinions on the third-party website. Sanofi shall not be responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information on the third party website or any errors, omissions or inaccuracies and/or incompleteness of the information on the third party website.
Right answer: Both A and B. As per Diabetic & Ramadan guidelines, T2DM patients can safely continue glargine U-100 once daily at a reduced dose of 15 - 30% at Iftar1,2. Insulin glargine U-100 is safe to be used during Ramadan with no significant increase in hypoglycaemia3. One-on-one dietary educational session can also reduce the number of adverse events of fasting1.
